Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Recurrence × cabazitaxel × Clear all

Phase

Phase 2 5 Phase 3 1 Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 3 Neoplasms 2 Recurrence 1 Prostatic Neoplasms, Castration-Resistant 1 Metastatic Castration-resistant Prostate Cancer 1 Malignant Solid Tumor - Malignant Nervous System Neoplasm 1 Carcinoma 1

Interventions

Dexamethasone 24 Cyclophosphamide 21 venetoclax 17 fludarabine 12 Lenalidomide 12 Bortezomib 12 pembrolizumab 11 Cytarabine 11 Carboplatin 10 Calcium Dobesilate 10 Rituximab 8 pomalidomide 7 Nivolumab 7 Gemcitabine 7 Azacitidine 7 fludarabine phosphate 6 carfilzomib 6 selinexor 5 daratumumab 5 blinatumomab 5 Temozolomide 5 Decitabine 5 Cisplatin 5 Bendamustine Hydrochloride 5 obinutuzumab 4 ibrutinib 4 elotuzumab 4 Methotrexate 4 Etoposide 4 Cetuximab 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02202772 2025-02-24

CGC

Columbia University

Phase 1/2 Active not recruiting

Carcinoma, Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡